- Home
- NUTR vs CLSD Comparison
NUTR vs CLSD Comparison
Compare NUTR & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUTR
- CLSD
- Stock Information
- Founded
- NUTR 2013
- CLSD 2011
- Country
- NUTR Indonesia
- CLSD United States
- Employees
- NUTR N/A
- CLSD N/A
- Industry
- NUTR
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- NUTR
- CLSD Health Care
- Exchange
- NUTR Nasdaq
- CLSD Nasdaq
- Market Cap
- NUTR 73.6M
- CLSD 68.4M
- IPO Year
- NUTR 2025
- CLSD 2016
- Fundamental
- Price
- NUTR N/A
- CLSD $0.42
- Analyst Decision
- NUTR
- CLSD Hold
- Analyst Count
- NUTR 0
- CLSD 4
- Target Price
- NUTR N/A
- CLSD $4.33
- AVG Volume (30 Days)
- NUTR 1.2M
- CLSD 12.9M
- Earning Date
- NUTR 01-01-0001
- CLSD 08-08-2025
- Dividend Yield
- NUTR N/A
- CLSD N/A
- EPS Growth
- NUTR N/A
- CLSD N/A
- EPS
- NUTR N/A
- CLSD N/A
- Revenue
- NUTR $924,138.00
- CLSD $4,166,000.00
- Revenue This Year
- NUTR N/A
- CLSD $78.37
- Revenue Next Year
- NUTR N/A
- CLSD $17.79
- P/E Ratio
- NUTR N/A
- CLSD N/A
- Revenue Growth
- NUTR N/A
- CLSD N/A
- 52 Week Low
- NUTR $3.40
- CLSD $0.29
- 52 Week High
- NUTR $4.07
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- NUTR N/A
- CLSD 39.95
- Support Level
- NUTR N/A
- CLSD $0.40
- Resistance Level
- NUTR N/A
- CLSD $0.47
- Average True Range (ATR)
- NUTR 0.00
- CLSD 0.06
- MACD
- NUTR 0.00
- CLSD 0.01
- Stochastic Oscillator
- NUTR 0.00
- CLSD 26.87
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.